Table 5 Comparing women with and those without sexual dysfunction based on DSM-5 criteria (N = 126)
From: Evaluation of sexual dysfunction in gynecologic cancer survivors using DSM-5 diagnostic criteria
Parameters | Female sexual dysfunction (DSM-5) | p value | |
|---|---|---|---|
Yes (n = 55) | No (n = 71) | ||
Age, year (mean ± SD) | 42.33 ± 5.86 | 42.52 ± 6.65 | 0.872 |
Education | |||
Senior high school or less | 24 (43.6%) | 39 (54.9%) | 0.209 |
College/University or above | 31 (56.4%) | 32 (45.1%) | |
Residence | |||
Suburb | 23 (41.8%) | 33 (46.4%) | 0.456 |
City | 32 (58.2%) | 38 (53.6%) | |
Marital status | |||
Married | 46 (83.6%) | 58 (81.7%) | 0.775 |
Unmarried/divorced | 9 (16.4%) | 13 (18.3%) | |
Cancer type | |||
Endometrium* | 10 (18.2%) | 27 (38.0%) | 0.015 |
Ovary* | 23 (41.8%) | 18 (25.4%) | 0.051 |
Cervix | 20 (36.4%) | 25 (35.2%) | 0.893 |
Others | 3 (5.5%) | 3 (4.2%) | 0.748 |
FIGO stage | |||
I | 43 (78.2%) | 50 (90.9%) | 0.370 |
II–IV | 12 (21.8%) | 21 (9.1%) | |
Treatment | |||
Hysterectomy | 41 (74.5%) | 48 (67.6%) | 0.309 |
Oophorectomy | 21 (38.2%) | 21 (29.6%) | 0.275 |
Radiation | 15 (27.3%) | 13 (18.3%) | 0.182 |
Chemotherapy | 29 (52.7%) | 26 (36.6%) | 0.057 |
Time from treatment | |||
≤ 3 years | 36 (65.5%) | 36 (50.7%) | 0.115 |
> 3 years | 19 (34.5%) | 35 (49.2%) | |
Hormone replacement | 14 (25.5%) | 8 (11.3%) | 0.037 |
Self medical disease | 13 (23.6%) | 16 (22.9%) | 0.981 |
Partner medical disease | 13 (23.6%) | 10 (14.5%) | 0.160 |
Current medication | 22 (40.0%) | 25 (35.7%) | 0.623 |
Recurrent history | 4 (7.3%) | 2 (2.8%) | 0.249 |